Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

Inclusion Criteria: * Signed patient consent form * Chronic HCV patients in relapse following conventional treatment regimen (INF+Ribavirine) with detectable plasma level of HCV RNA * Hepatitis B and human immunodeficiency virus negative at screening visit * Able and willing to follow contraception requirements * Screening laboratory values, test, and physical exam within acceptable range Exclusion Criteria: * Current enrollment in another investigational device or drug study * Anticipated inability to complete all clinic visits and comply with study procedures * History of, or any current medical condition, which could impact the safety of the subject during the study * Autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease, or other known liver disease other than HCV * Alcoholism or substance abuse with \<6 documented months of sobriety * Known allergy or sensitivity to interferons or ribavirin * Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study